丙型肝炎病毒抑制剂替拉韦啶和HCV-796的GT-1a或GT-1b亚型特异性耐药谱。
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
作者信息
McCown Matthew F, Rajyaguru Sonal, Kular Simran, Cammack Nick, Nájera Isabel
机构信息
Roche Palo Alto LLC, 3431 Hillview Ave., Palo Alto, CA 94304, USA.
出版信息
Antimicrob Agents Chemother. 2009 May;53(5):2129-32. doi: 10.1128/AAC.01598-08. Epub 2009 Mar 9.
Abstract
In vitro, telaprevir selects subtype-specific resistance pathways for hepatitis C virus GT-1a and GT-1b, as described to have occurred in patients. In GT-1a, the HCV-796 resistance mutation C316Y has low replication capacity (7%) that can be compensated for by the emergence of the mutation L392F or M414T, resulting in an increase in replication levels of > or = 10-fold.
摘要
在体外，特拉匹韦会为丙型肝炎病毒GT-1a和GT-1b选择亚型特异性耐药途径，正如在患者中所发生的那样。在GT-1a中，HCV-796耐药突变C316Y的复制能力较低（7%），可通过L392F或M414T突变的出现得到补偿，导致复制水平增加≥10倍。
相似文献
1
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.丙型肝炎病毒抑制剂替拉韦啶和HCV-796的GT-1a或GT-1b亚型特异性耐药谱。
Antimicrob Agents Chemother. 2009 May;53(5):2129-32. doi: 10.1128/AAC.01598-08. Epub 2009 Mar 9.
2
[Telaprevir resistance].[替拉普韦耐药性]
Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6.
3
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.基线丙型肝炎病毒 (HCV) NS3 多态性及其对 HCV NS3 蛋白酶抑制剂法地昔洛韦临床研究中治疗反应的影响。
Antimicrob Agents Chemother. 2014;58(2):698-705. doi: 10.1128/AAC.01976-13. Epub 2013 Nov 11.
4
Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.来自地瑞那韦和法达普韦临床研究的丙型肝炎病毒NS3/4A蛋白酶和NS5B聚合酶的耐药性分析
PLoS One. 2016 Aug 5;11(8):e0160668. doi: 10.1371/journal.pone.0160668. eCollection 2016.
5
A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.利用超深度测序对丙型肝炎使用序贯直接作用抗病毒药物的耐药性出现进行的转化研究。
Am J Gastroenterol. 2013 Sep;108(9):1464-72. doi: 10.1038/ajg.2013.205. Epub 2013 Jul 30.
6
Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease.鉴定 V36C，一种赋予 HCV 对 HCV 蛋白酶强效拟肽抑制剂特拉匹韦耐药性的新型氨基酸取代。
Antimicrob Agents Chemother. 2010 Jun;54(6):2681-3. doi: 10.1128/AAC.01796-09. Epub 2010 Apr 5.
7
[Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].[抗病毒治疗期间丙型肝炎病毒基线多态性的意义]
Orv Hetil. 2015 May 24;156(21):849-54. doi: 10.1556/650.2015.30180.
8
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.体外对丙型肝炎病毒 NS3 蛋白酶抑制剂 BI 201335 的耐药谱。
Antimicrob Agents Chemother. 2012 Jan;56(1):569-72. doi: 10.1128/AAC.05166-11. Epub 2011 Oct 24.
9
[Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].[1型基因型感染的慢性丙型肝炎患者中NS3抑制剂耐药突变的测定]
Mikrobiyol Bul. 2017 Apr;51(2):145-155. doi: 10.5578/mb.53824.
10
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.丙型肝炎病毒（HCV）1b基因型复制子系统中蛋白酶抑制剂耐药性HCV NS3蛋白酶突变体的相对复制能力和选择性优势概况
Antimicrob Agents Chemother. 2008 Mar;52(3):1101-10. doi: 10.1128/AAC.01149-07. Epub 2007 Dec 17.
引用本文的文献
1
Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil.使用来自巴西圣保罗州的干血斑同时测定丙型肝炎病毒（HCV）基因型和NS5B耐药相关替代位点
Access Microbiol. 2022 Mar 2;4(3):000326. doi: 10.1099/acmi.0.000326. eCollection 2022.
2
Hepatitis C Virus Vaccine: Challenges and Prospects.丙型肝炎病毒疫苗：挑战与前景
Vaccines (Basel). 2020 Feb 17;8(1):90. doi: 10.3390/vaccines8010090.
3
Computational analysis of naturally occurring resistance-associated substitutions in genes , , and among 86 subtypes of hepatitis C virus worldwide.全球86种丙型肝炎病毒亚型中基因 、 和 中天然存在的抗性相关替代的计算分析。
Infect Drug Resist. 2019 Sep 19;12:2987-3015. doi: 10.2147/IDR.S218584. eCollection 2019.
4
The horizon: New targets and new agents.新视野：新靶点与新药物
Clin Liver Dis (Hoboken). 2012 Mar 6;1(1):24-27. doi: 10.1002/cld.2. eCollection 2012 Feb.
5
Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients.鉴定未经治疗的患者血浆和肝脏中针对直接作用抗病毒药物的 HCV 耐药变异体。
Sci Rep. 2017 Jul 5;7(1):4688. doi: 10.1038/s41598-017-04931-y.
6
Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.丙型肝炎病毒（HCV）聚合酶变构抑制剂的生物物理作用模式及选择性分析
Viruses. 2017 Jun 16;9(6):151. doi: 10.3390/v9060151.
7
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance.直接作用抗病毒药物治疗慢性丙型肝炎：耐药性的作用。
World J Gastroenterol. 2016 Aug 7;22(29):6573-81. doi: 10.3748/wjg.v22.i29.6573.
8
Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.Geno2pheno[丙型肝炎病毒]——一种基于网络的解读系统，用于在直接抗病毒药物时代辅助丙型肝炎治疗决策。
PLoS One. 2016 May 19;11(5):e0155869. doi: 10.1371/journal.pone.0155869. eCollection 2016.
9
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.达诺瑞韦联合利托那韦方案治疗初治和既往无应答的 HCV 基因 1 或 4 型及代偿性肝硬化患者。
Hepatol Int. 2016 May;10(3):478-87. doi: 10.1007/s12072-015-9699-9. Epub 2016 Feb 17.
10
Synthesis and biological evaluation of sophocarpinic acid derivatives as anti-HCV agents.槐果碱酸衍生物作为抗丙型肝炎病毒药物的合成及生物学评价
Acta Pharm Sin B. 2014 Aug;4(4):307-12. doi: 10.1016/j.apsb.2014.06.002. Epub 2014 Jul 15.
本文引用的文献
1
Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.对苯并呋喃抑制剂HCV-796敏感性降低的丙型肝炎病毒复制子变体的分子机制
Antimicrob Agents Chemother. 2008 Sep;52(9):3327-38. doi: 10.1128/AAC.00238-08. Epub 2008 Jun 16.
2
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.丙型肝炎病毒复制子对核苷类似物的耐药性屏障高于对非核苷聚合酶或蛋白酶抑制剂的耐药性屏障。
Antimicrob Agents Chemother. 2008 May;52(5):1604-12. doi: 10.1128/AAC.01317-07. Epub 2008 Feb 19.
3
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.特拉匹韦和聚乙二醇化干扰素-α-2a可抑制患者体内野生型和耐药性1型丙型肝炎病毒的复制。
Hepatology. 2007 Sep;46(3):631-9. doi: 10.1002/hep.21781.
4
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.使用蛋白酶抑制剂特拉匹韦治疗的患者中丙型肝炎病毒的动态基因和表型变化。
Gastroenterology. 2007 May;132(5):1767-77. doi: 10.1053/j.gastro.2007.02.037. Epub 2007 Feb 21.
5
Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.丙型肝炎病毒拇指结合和手掌结合非核苷类聚合酶抑制剂双重耐药复制子变体的筛选与鉴定
J Virol. 2006 Jun;80(12):6146-54. doi: 10.1128/JVI.02628-05.
6
In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.体外筛选出的对2'-C-甲基胞苷或R1479耐药的Con1亚基因组复制子显示不存在交叉耐药性。
Virology. 2006 Aug 1;351(2):349-59. doi: 10.1016/j.virol.2006.03.045. Epub 2006 May 19.
7
The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.新型核苷类似物R1479（4'-叠氮胞苷）是细胞培养中NS5B依赖性RNA合成和丙型肝炎病毒复制的有效抑制剂。
J Biol Chem. 2006 Feb 17;281(7):3793-9. doi: 10.1074/jbc.M510195200. Epub 2005 Nov 29.
8
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.针对两种丙型肝炎病毒丝氨酸蛋白酶抑制剂VX-950和BILN 2061的交叉耐药性突变的体外研究。
J Biol Chem. 2005 Nov 4;280(44):36784-91. doi: 10.1074/jbc.M506462200. Epub 2005 Aug 8.
9
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.丙型肝炎病毒丝氨酸蛋白酶抑制剂VX-950和BILN 2061的体外耐药性研究：结构分析表明存在不同的耐药机制。
J Biol Chem. 2004 Apr 23;279(17):17508-14. doi: 10.1074/jbc.M313020200. Epub 2004 Feb 6.
10
Replication studies using genotype 1a subgenomic hepatitis C virus replicons.使用1a基因型丙型肝炎病毒亚基因组复制子的复制研究。
J Virol. 2003 May;77(9):5352-9. doi: 10.1128/jvi.77.9.5352-5359.2003.
Zotero 插件